**MANAGEMENT OF ONCOGENIC TRANSFORMATION**
**BY INTERFERING WITH THE ACTION OF ACTIVATOR PROTEIN-1**

**AKTİVATÖR PROTEİN-1’İN ETKİSİNİN KULLANARAK ONKOJENİK TRANSFORMASYONU YÖNLENDİRMEK**

Nurullah KEKLİKOĞLU*, Meltem KORAY**, Ilker BOLAT*, Sevtap AKINCI *

**ABSTRACT**
Immediate Early Genes (IEGs) are the foremost genes to respond to any stimuli within the cell. This group of genes are in fact transcription factors which are associated with the growth, proliferation, differentiation and apoptosis of the cells. Fos proteins produced by c-fos gene, which is an IEG, and Jun proteins produced by c-jun gene, which is also an IEG, are the components of the transcription factor complex, namely the Activator Protein-1 (AP-1), and they act together. The members of the AP-1 complex modulate various gene expressions. All AP-1 proteins regulate certain aspects of the cellular responses to growth factors. These components are critically linked to many cellular processes including growth, proliferation, differentiation, apoptosis, and oncogenic transformation. Carcinogenesis resulting from the impairment in the cellular processes controlled by IEGs and AP-1 has been described. Besides the vital importance of their normal cellular expressions, the abnormal expressions of IEGs and AP-1 could cause serious problems such as oncogenic transformation. There are several ongoing studies about the substances and effectors causing overexpression or inhibition of AP-1. If the stages of oncogenic transformation and the role of AP-1 and IEGs in this transformation can be illuminated, carcinogenesis could be taken under control as well as some of the peculiarities of malignant cells could be beneficial for the treatments of various diseases.

**Key words:** IEGs, AP-1, Carcinogenesis, Proto-oncogenes, Oncoproteins, Oncogenic transformation.

**ÖZET**

**Anahtar kelimeler:** IEG, AP-1, Karsinogenez, Protoonkojenler, Onkoproteinler, Onkojenik transformasyon.

**INTRODUCTION**
Immediate Early Genes (IEGs) and Activator Protein -1 (AP-1) family proteins which contain their oncoprotein products, are required for the maintenance of the vitality and regeneration of cells. Besides the vital importance of their normal cellular expressions, the abnormal expressions of IEGs and AP-1 could cause serious problems such as oncogenic transformation. If the role of AP-1 in onco-
genic transformation can be elucidated, characteristics of cancer cells could be utilized in the treatments of various disorders.

IEGs are potential activators of transcription and IEGs are the first genes to respond to any stimuli within the cell (7). IEGs and AP-1 play a very important role during cellular proliferation, differentiation, programmed cell death (apoptosis) and oncogenic transformation (4, 41). These proto-oncogenes and oncoproteins, being potential activators of transcription, are key elements to understand oncogenic transformation and normal development due to their relationship with biological processes. The pathways regulating different cell cycle phases are the central target for genetic alterations in cancer due to their interaction with various oncogenes and tumor suppressors (15). The transcription factors are fundamental to the progression of genetic and cellular changes which culminate in a malignant tumor (40). In some tumor types, c-fos and c-jun levels, both of which are IEGs, have been shown to increase, and it was suggested that this elevation may play an important role in tumorigenesis, since it is a sign of increased proliferation (14, 27). However, in addition to their role in malignancy, proto-oncogenes are also involved in the regulation of normal growth and differentiation.

Many mitogens may stimulate IEGs, and therefore the protein product of these proto-oncogenes are referred to as oncoproteins. These proteins are known to play a role in the development of cancer (46). Fos proteins produced by c-fos gene and Jun proteins produced by c-jun gene are the components of the transcription factor complex, namely the Activator Protein-1 (AP-1) (16). AP-1 consists of Fos proteins (c-Fos, Fos B, Fra 1, Fra 2), Jun proteins (c-Jun, Jun B, Jun D), and some activating transcription factor (ATF) proteins (ATFa, ATF-1, ATF-2, ATF-3) (12, 25). Fos proteins form stable dimers with Jun proteins. On the other hand, Jun proteins form homodimers or heterodimers with Fos and ATF proteins (2, 14, 25). All AP-1 proteins regulate certain aspects of the cellular response to growth factors and tumor promoting phorbol esters (2). These stimuli can stimulate AP-1 activity by activating mitogen-activated protein kinases (MAPK), such as extracellular...
lar signal-regulated kinase (ERK), c-Jun N-terminal kinase or stress-activated protein kinase (JNK/SAPK) and p38 kinase (19). Induced AP-1 activity is required for tumor promoter-induced transformation (10) (Figure 1).

It is known that IEGs and AP-1 are key factors in carcinogenesis (18, 37, 50). Carcinogenesis develops in three defined stages; initiation, promotion, and progression (36). Transactivation of AP-1 is important in traversing tumor promotion and/or progression stages of carcinogenesis (50). According to a claim, c-fos expression is involved in benign-to-malignant tumor progression (17).

It is possible to block carcinogenesis or inactivate cancer cells by inhibiting the transcriptional activity of AP-1 or AP-1 expression. Since AP-1 inhibitors respond to peptide growth factors like insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), heregulin-beta and basic fibroblast growth factor (bFGF) by completely blocking proliferation, AP-1 blockade suppresses mitogenic signal from multiple different peptide growth factors (31). The incidence of cancer increases with age (3). A possible contributing factor may be that the level of AP-1 activity varies throughout the life time of both a cell and an individual. It has been suggested that IEG and AP-1 activity, which are high during embryonic development, may be altered by ageing. Cellular ageing results in significant changes in the composition and DNA-binding capacity of AP-1 transcription factor (43). Cellular ageing is characterized by many phenotypic changes such as the alteration in the proliferative capacity of gene expression, impairment in the stimulation of c-fos by serum, and alterations in the binding activity of Serum Response Factor (SRF). These changes are associated with decrease in c-fos expression in the older cells (32, 47).

According to the results of some studies, AP-1 proteins can substitute each others antagonistic functions in biological processes such as oncogenic transformation and cell proliferation and each of AP-1 proteins may have different individual functions (23, 26, 44). There are some different implications for these transcription factors according to tumour type, for example, Fra-1 overexpression enhances the motility and invasion of breast and colorectal cancer cells, but inhibits the tumourigenicity of cervical carcinoma cell lines (35). It is also claimed that some proteins belonging to Jun and Fos families, like Jun B and c-Fos, have tumour-suppressor activity and can suppress tumour formation. The decision as to whether AP-1 is oncogenic or anti-oncogenic depends on the cell type, differentiation state, tumour stage and the genetic background of the tumour (11).

The genes some of which have a potential to mediate neoplastic transformation, are regulated by AP-1 (1). Therefore the studies to determine substances and mechanisms which are able to inhibit AP-1 activation are crucial steps in the progress of controlling carcinogenesis (21, 29, 31, 52). There are ongoing studies pointing that the biologic mechanisms or curative substances inhibit growth or invasion in cancer cells through repression or blocking of AP-1 activity (6, 20, 22, 34, 39, 49). It is known that dominant-negative cJun mutant (TAM67) (18, 31, 34) and Jun dimerization protein 2 (JDP2) (32) are specific inhibitors of AP-1. It has been reported that TAM67 inhibits breast cancer growth by inducing inhibitors of cyclin-dependent kinases (such as p27) and by reducing the expression of the cyclins involved in transitioning from G1 into S phase of the cell cycle (30). It has been shown that protein kinase C (PKC) inhibitors like Calphostin C and bisindolylmaleimide I also inhibit AP-1 activation and phosphorylation of MAPKs (ERKs and p38 kinases) (9).

TRIM45 one of the tripartite motif (TRIM) proteins (48), Costunolide, a sesquiterpene lactone isolated from the root of Saussurea lapa Clarke [24], Gabexate mesilate, a synthetic protease inhibitor (51), Rhein (4,5-Dihydroxyanthraquinone-2-carboxylic acid), a constituent enriched in the rhizome of rhubarb (R. palmatum L. or R. tanguticum Maxim) (29), inhibit the activity of AP-1 transcription factor.

According to the result of a previously performed study; inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth (31). Moreover, different cases about blocking AP-1 activity have also been reported in another studies, including blocking AP-1 activation using Ursodeoxycholic acid (UDCA) in order to block colonic carcinogenesis (42), inhibition of breast cancer cell growth by means of using overexpression of TAM67 (a dominant-negative form of cJun) (33) and inhibition of both AP-1 activation and translation initiation by programmed cell death 4 (PDCD4) while decreasing benign tumor development and malignant progression (21).

By AP-1 inhibition, it is possible to inhibit matrix metalloproteinases (MMPs) which are important factors in tumor invasion and metastasis. Treatment of human fibrosarcoma cells with Carboxylated chitoooligosaccharides (CCOS) leads to down-regulation of AP-1, which results in inhibition of matrix metalloproteinase-9 (MMP-9) (38). Moreover, treatment of human breast carcinoma cells with silibinin, a flavonoid antioxidant from milk thistle (Silybum marianum L.) suppresses AP-1 dependent MMP-9 gene expression by blocking the activation of AP-1 via MAPK signaling pathways (28).

Carcinogenesis resulting from the impairment in the cellular processes controlled by IEGs and AP-1 has been described. The abnormal expressions of oncogenes, oncoproteins and tumor suppressors disorder normal cell cycle. This incident brings new characteristics to these cells. The ability of a tumor cell to avoid programmed cell death (apoptosis) is crucial in the development of cancer (8). The acquisition of cellular immortality is a crucial step in human tumorigenesis (45).

Systemic activation or inactivation of IEGs and AP-1 may help to control the carcinogenesis invoked by inadequate or over-activation of IEGs and AP-1. The carcinogenesis progress can also be taken under control by analyzing and
fully revealing cancer cell characteristics such as immor-
tality-evasion from apoptosis, metastasis, continuous divi-
sion- proliferation and unaging. By controlling this pro-
cess, mentioned peculiarities of cancer cells can be utili-
zed to discover new treatment approaches or develop cur-
current treatment procedures. Therefore it may be possible to
prevent cell and tissue based disorders such as cell-ageing,
growth retardation and it may be also possible to compen-
sate loss of tissue integrity due to several reasons.

REFERENCES

1- Angel P, Imagawa M, Chiu R, Stein B, Imbra RJ, Rahmsdorf

2- Angel P, Karin M. The role of Jun, Fos and the AP-1 comp-

3- Anisimov VN. Biology of aging and cancer. Cancer Control

4- Bakiri L, Matsuo K, Wisniewska M, Wagner EF, Yaniv M. 
Promoter specificity and biological activity of tethered AP-1 

5- Bossis G, Malnou CE. Farras R, Andermarcher E, Lipskind 
R, Rodriguez M, Schmidt D, Muller S, Jariel-Encontre I, Pi-
echaczek Y. Down-regulation of c-Fos/c-Jun AP-1 dimer 

6- Chun KS, Kim SH, Song YS, Surh YJ. Celecoxib inhibits 
phorbol ester-induced expression of COX-2 and activati-
on of AP-1 and p38 MAP kinase in mouse skin. Carcinogenesis 

7- Clayton DF. The genomic action potential. Neurobiol Learn 

8- Crighton D, Ryan KM. Splicing DNA-damage responses to 
tumour cell death. Biochim Biophys Acta 2004;1705:3-
1715.

9- Ding M, Huang C, Lu Y, Bowman L, Castranova V, Vallyat-
han V. Involvement of protein kinase C in crystalline silica-
induced activation of the MAP kinase and AP-1 pathway. 

10- Dong Z., Biker MJ, Watts RG, Matrisian LM, Colburn NH. 
Blocking of tumor promoter-induced AP-1 activity inhibits 
induced transformation in JB6 mouse epidermal cells. Proc 

11- Eferl R, Wagner EF. AP-1: A double-edged sword in tumo-

12- Fleischmann A, Hafezi F, Elliott C, Remc EC, Rüther U, 
Wagner FE. Fra-1 replaces c-Fos-dependent functions in mi-

13- Foletta VC. Transcription factor AP-1, and the role of Fra-2. 

14- Franchi A, Calzolari A, Zampi G. Immunohistochemical detec-
tion of c-fos and c-jun expression in osseous and cartila-


16- Glover JNM, Harrison SC. Crystal structure of the Heterodi-
meric bZIP Transcription Factor c-fos/ c-Jun Bound to 

17- Greenhalgh DA, Wang XJ, Eckhardt JN, Roop DR. 12-O-
tetradecanoylphorbol-13-acetate promotion of transgenic 
mice expressing epidermal-targeted v-fos induces rasHA-ac-
тивated papillomas and carcinomas without p53 mutation: 
asociation of v-fos expression with promotion and tumor au-

18- Hemmigan RF, Stambrook PJ. Dominant negative c-jun inhib-
its activation of the cyclin D1 and cyclin E kinase complex-

19- Hou DX, Kai K, Li JJ, Lin S, Terahara N, Wakamatsu M, Fu-
jii M, Young MR, Colburn N. Antithyocanidins inhibit activ-
ator protein 1 activity and cell transformation: structure-acti-
ivity relationship and molecular mechanisms. Carcinogenesis 

20- Huang Q, Shen HM, Ong CN. Inhibitory effect of emodin on 
tumor invasion through suppression of activator protein-1 
and nuclear factor-kappaB. Biochem Pharmacol 

21- Jansen AP, Camalier CE, Colburn NH. Epidermal express-
ion of the translation inhibitor programmed cell death 4 sup-

22- Jin C, Li H, Murata T, Sun K, Horikoshi M, Chiu R, Yoko-
yama KK. JDP2, a repressor of AP-1, recruits a histone de-
acetylase 3 complex to inhibit the retinoic acid-induced dif-

23- Jochum W, Passegue E, Wagner EF. AP-1 in mouse develop-
ment and tumorigenesis. Oncogene 2001;20:2401_2412.

24- Kang JS, Yoon YD, Lee KH, Park SK, Kim HM. Costunoli-
de inhibits interleukin-1beta expression by down-regulation 
of AP-1 and MAPK activity in LPS-stimulated RAW 264.7 

25- Karin M, Zhend-gang L, Zandi E. AP-1 function and regu-

26- Keklikoglu N. The localization of Fos B, a member of transcription factor AP-1 family, in rat odontoblasts and pul-
pal undifferentiated ectomesenchymal cells. Folia Histoc-

27- Lee CS, Charalambous D. Immunohistochemical localisati-
on of the c-fos oncprotein in pancreatic cancer. Zentralbl Pathol 

28- Lee SO, Jeong YJ, Im HG, Kim CH, Chang YC, Lee IS. Si-
lubinin suppresses PMA-induced MMP-9 expression by 
blocking the AP-1 activation via MAPK signaling pathways in 
MCF-7 human breast carcinoma cells. Biochem Biophys Res 

29- Lin S, Li JJ, Fujii M, Hou DX. Rhein inhibits TPA-induced 
activator protein-1 activation and cell transformation by 
blocking the JNK-dependent pathway. Int J Oncol 

PH. AP-1 blockade in breast cancer cells causes cell cycle 
 arrest by suppressing Glcycbin expression and reducing 
cyclin-dependent kinase activity. Oncogene 2004;23:8238-
8246.

Onkojenik transformasyonu yönlendirmek


